PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Lurbinectedin for Neuroendocrine Tumors (NETs)

Lurbinectedin for Neuroendocrine Tumors (NETs)
2023-10-06
(Press-News.org)

“Several ongoing trials hope to further elucidate the role of lurbinectedin in highgrade neuroendocrine neoplasms [...]”

BUFFALO, NY- October 6, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on June 14, 2023, entitled, “Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer.”

In their new editorial, researchers Deepak Bhamidipati and Vivek Subbiah from the Sarah Cannon Research Institute discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs). NETs encompass a variety of neoplasms which display a wide spectrum of biologic behavior, ranging from the aggressive neuroendocrine carcinoma (NEC) to often indolent well-differentiated NETs. 

For well-differentiated NETs, somatostatin analogs (SSAs) are widely accepted as an effective frontline therapy for progressive or symptomatic disease; however, subsequent therapy options such as capecitabine/ temozolomide, sunitinib, everolimus, and radionuclide therapy in selected cases are associated with variable response rates (typically less than 20%) and limited progression-free survival. NECs can respond to platinum-based chemotherapy, but responses are typically short-lived. 

“There is evidence to suggest that neuroendocrine neoplasms such as small-cell lung cancer (SCLC) and pancreatic NETs are responsive to DNA alkylators such as temozolomide.”

Recently, lurbinectedin a DNA minor groove inhibitor and marine derivative was shown to inhibit oncogenic transcription through binding to CG-rich sequences near the promoters of protein-coding genes to promote apoptosis and cell death. Encouraging results from a phase II basket study of lurbinectedin as a second-line treatment for patients with SCLC, which demonstrated a 35% response rate, resulted in the FDA-approval of lurbinectedin in pre-treated patients with SCLC. Moreover, in a subset analysis lurbinectedin was shown to be an effective treatment for platinum-sensitive relapsed SCLC, especially in patients with chemotherapy-free interval (CTFI) ≥180 days with an objective response rate of over 60%. It was shown to be active in BRCA1/2 germline mutated breast cancer. In addition, it is active in Ewing sarcoma, another small round-cell tumor of neuroendocrine origin. 

“This bolstered the hypothesis that lurbinectedin could demonstrate activity in additional malignancies of neuroendocrine origin.”

 

Read the full editorial: DOI: https://doi.org/10.18632/oncoscience.579 

Correspondence to: Vivek Subbiah

Email: Vivek.Subbiah@sarahcannon.com 

Keywords: lurbinectedin, neuroendocrine tumors, NET, small cell lung cancer
 

About Oncoscience: 

Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.

To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:

X, formerly known as Twitter  Facebook  YouTube  LinkedIn   

For media inquiries, please contact media@impactjournals.com.

 

Oncoscience Journal Office

6666 East Quaker Str., Suite 1D

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 4

###

END


[Attachments] See images for this press release:
Lurbinectedin for Neuroendocrine Tumors (NETs) Lurbinectedin for Neuroendocrine Tumors (NETs) 2

ELSE PRESS RELEASES FROM THIS DATE:

Clinical trial reveals benefits of inhaled nitric oxide for patients with respiratory failure due to COVID-19 pneumonia

2023-10-06
Key Takeaways Researchers have posted the results of a multisystem phase II clinical trial of patients with COVID-19 and respiratory failure Patients who received inhaled nitric oxide had improved blood oxygen levels and fewer risks of long-term sensory and motor neurologic symptoms They also experienced a faster reduction of viral load in sputum and blood BOSTON – Inhaled nitric oxide gas widens blood vessels in the lungs and is used to treat severe cardio-pulmonary conditions in newborns and adults. A recent multicenter international ...

nTIDE September 2023 Jobs Report: Employment trend holds steady at historic highs through early autumn for people with disabilities

nTIDE September 2023 Jobs Report: Employment trend holds steady at historic highs through early autumn for people with disabilities
2023-10-06
East Hanover, NJ – October 6, 2023 –The labor force participation and employment-to-population ratio have held relatively steady throughout the summer and into the fall for people with disabilities, while percentages for people without disabilities may have maxed out at their pre-pandemic baseline, according to today’s National Trends in Disability Employment – semi-monthly update (nTIDE), issued by Kessler Foundation and the University of New Hampshire’s Institute on Disability (UNH-IOD). In comparison, the employment-to-population ratio for people without disabilities remained flat with no change, while ...

Kidney disease gene also has a protective mutation

Kidney disease gene also has a protective mutation
2023-10-06
African Americans have long been known to be at increased risk of kidney disease due to a dangerous genetic mutation that creates a hole in the kidney cells, but Vanderbilt University Medical Center (VUMC) researchers have now discovered a protective genetic mutation that covers the hole to eliminate the risk.   The findings on the apolipoprotein L1 (APOL1) gene, published today in the Journal of the American Society of Nephrology, could have immediate and broad implications for kidney health because people with both the disease-causing and protective mutation are not at increased risk.   “Our team discovered ...

Aston University offers talented Indian graduates opportunity to study for Masters degrees

Aston University offers talented Indian graduates opportunity to study for Masters degrees
2023-10-06
Aston University, UK, is offering a group of highly talented graduates of Symbiosis Institute of Technology (SIT), India the opportunity to study for a Masters degree.   The two institutions have signed a progression agreement which is designed to make it easier for top SIT graduates to apply for courses at Aston University.   The Aston-SIT partnership has been developed from the support of the British Council via its going global partnerships exploratory grant scheme. The areas of study cover a wide range of MSc programmes in engineering, physical sciences and business studies.   Aston University is in Birmingham, ...

New research led by Mays Cancer Center reveals how mutations in BRCA1 affect cancer susceptibility in women

2023-10-06
SAN ANTONIO, Oct. 6, 2023 – Three decades after discoveries linking mutations in the BRCA1 gene to breast and ovarian cancer susceptibility, research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has pinpointed the molecular mechanism by which a large portion of these mutations cause cancers in women. The discovery, unveiled in an Oct. 4 research article in the journal Molecular Cell, is poised to assist researchers in developing drugs to battle breast and ovarian cancers and to help identify women who are at an elevated risk of developing these cancers, according to the ...

How the war in Ukraine is challenging two academic disciplines

How the war in Ukraine is challenging two academic disciplines
2023-10-06
Since the beginning of Russia’s invasion of Ukraine, two academic disciplines have come to fore: peace and conflict studies and East European studies. Experts from both fields represent important voices in the public discourse. A symposium entitled ‘War and Peace in Ukraine: Reflecting, Studying and Engaging Across Disciplines” will be held from 12 until 13 October 2023 at Bielefeld University. It brings together experts from both fields in order to discuss the relationship between them and challenges of participating in a highly ...

How do our brains tell us what went wrong?

2023-10-06
Whether improperly closing a door or shanking a kick in soccer, our brains tell us when we’ve made a mistake because these sounds differ from what we expect to hear. While it’s long been established that our neurons spot these errors, it has been unclear whether there are brain cells that have only one job—to signal when a sound is unexpected or “off.” A team of New York University neuroscientists has now identified a class of neurons—what it calls “prediction-error neurons”—that are not responsive to sounds in general, ...

New pathways of Alzheimer's disease identified

2023-10-06
Dementia, which includes Alzheimer's disease, currently affects around 1.8 million people in Germany. The exact cause has not yet been clarified, but genetic factors play a significant role in the development of the disease.  Most previous analyses aimed at the identification of novel Alzheimer's genes used, a "case-control design". "With this conventional and highly simplistic analysis strategy, a vast amount of clinical information is lost that can be valuable for elucidating new disease mechanisms," says Prof. Dr. Lars Bertram, head of the Lübeck Interdisciplinary Platform for Genome Analysis at the University ...

Consistent metabolism may prove costly for insects in saltier water

2023-10-06
Increased salinity usually spells trouble for freshwater insects like mayflies. A new study from North Carolina State University finds that the lack of metabolic responses to salinity may explain why some freshwater insects often struggle in higher salinity, while other freshwater invertebrates (like mollusks and crustaceans) thrive. Salinity in this case refers to the concentrations of all the salts in an aquatic environment, not just sodium. “Freshwater habitats in general are getting saltier for a number of reasons, including road salt and ...

Clinical trials: two arms are better than one

2023-10-06
The German Institute for Quality and Efficiency in Health Care (IQWiG) has responded critically to a reflection paper by the European Medicines Agency (EMA) on the approval of new drugs based on single-arm studies. The EMA correctly points out that studies without a control arm are subject to bias and that, in general, it is hardly possible to estimate causal effects from them. However, it does not provide clear criteria for limiting drug approval based on such studies to extremely rare exceptional cases. The FDA shows how to do it There is also no recommendation on external controls - in contrast to guidance published ...

LAST 30 PRESS RELEASES:

Testing thousands of RNA enzymes helps find first ‘twister ribozyme’ in mammals

Groundbreaking study provides new evidence of when Earth was slushy

International survey of more than 1600 biomedical researchers on the perceived causes of irreproducibility of research results

Integrating data from different experimental approaches into one model is challenging – this study presents a community-based, full-scale in silico model of the rat hippocampal CA1 region that integra

SwRI awarded grant to characterize Las Moras Springs watershed

Water overuse in MATOPIBA could mean failure to meet up to 40% of local demand for crop irrigation

An extra year of education does not protect against brain aging

Researchers from Uppsala and Magdeburg obtain an ERC Synergy Grant to advance cancer immunotherapy

Deaf male mosquitoes don’t mate

Recognizing traumatic brain injury as a chronic condition fosters better care over the survivor’s lifetime

SwRI’s Dr. James Walker receives Distinguished Scientist Award from Hypervelocity Impact Society

A mother’s health problems pose a risk to her children

Ensuring a bright future for diamond electronics and sensors

The American Pediatric Society selects Dr. Maria Trent as the Recipient of the 2025 David G. Nichols Health Equity Award

The first 3D view of the formation and evolution of globular clusters

Towards a hydrogen-powered future: highly sensitive hydrogen detection system

Scanning synaptic receptors: A game-changer for understanding psychiatric disorders

High-quality nanomechanical resonators with built-in piezoelectricity

ERC Synergy Grants for 57 teams tackling major scientific challenges

Nordic research team receives €13 million to explore medieval book culture 

The origin of writing in Mesopotamia is tied to designs engraved on ancient cylinder seals

Explaining science through dance

Pioneering neuroendocrinologist's century of discovery launches major scientific tribute series

Gendered bilingualism in post-colonial Korea

Structural safety monitoring of buildings with color variations

Bio-based fibers could pose greater threat to the environment than conventional plastics

Bacteria breakthrough could accelerate mosquito control schemes

Argonne to help drive AI revolution in astronomy with new institute led by Northwestern University

Medicaid funding for addiction treatment hasn’t curbed overdose deaths

UVA co-leads $2.9 million NIH investigation into where systems may fail people with disabilities

[Press-News.org] Lurbinectedin for Neuroendocrine Tumors (NETs)